| 0.057 0 (0%) | 04-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.14 |
1-year : | 0.23 |
| Resists | First : | 0.12 |
Second : | 0.19 |
| Pivot price | 0.01 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 |
MA(20) : | 0.01 |
| MA(100) : | 0.41 |
MA(250) : | 1.28 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.1 |
D(3) : | 7.8 |
| RSI | RSI(14): 23 |
|||
| 52-week | High : | 4.25 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CDAK ] has closed above bottom band by 44.9%. Bollinger Bands are 95.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.02 - 0.02 | 0.02 - 0.02 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Mon, 27 Mar 2023
Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process - Yahoo Finance
Mon, 27 Mar 2023
Why Is Codiak BioSciences (CDAK) Stock Down 52% Today? - InvestorPlace
Mon, 27 Mar 2023
Codiak BioSciences Files For Chapter 11 Bankruptcy - Yahoo Finance
Mon, 27 Mar 2023
Cash-strapped biotech firm Codiak files for bankruptcy protection - Reuters
Tue, 30 Aug 2022
Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring - GlobeNewswire
Mon, 02 May 2022
Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 37 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 71.5 (%) |
| Shares Short | 174 (K) |
| Shares Short P.Month | 170 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.05 |
| Profit Margin | -51.2 % |
| Operating Margin | -154.5 % |
| Return on Assets (ttm) | -22.5 % |
| Return on Equity (ttm) | -47.8 % |
| Qtrly Rev. Growth | -55 % |
| Gross Profit (p.s.) | -1.14 |
| Sales Per Share | 0.92 |
| EBITDA (p.s.) | -1.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -67 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.01 |
| Price to Sales | 0.01 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|